6-(三氟甲基)嘧啶衍生物TLR8拮抗剂的优化。

IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Nika Strašek Benedik, Valerij Talagayev, Troy Matziol, Ana Dolšak, Izidor Sosič, Günther Weindl, Gerhard Wolber, Matej Sova
{"title":"6-(三氟甲基)嘧啶衍生物TLR8拮抗剂的优化。","authors":"Nika Strašek Benedik, Valerij Talagayev, Troy Matziol, Ana Dolšak, Izidor Sosič, Günther Weindl, Gerhard Wolber, Matej Sova","doi":"10.2478/acph-2025-0011","DOIUrl":null,"url":null,"abstract":"<p><p>Toll-like receptors (TLRs) are essential for the innate immune system as they recognize pathogen-associated molecular patterns and trigger immune responses. Overactivation of TLR8 by endogenous nucleic acids is associated with the development of autoimmune diseases and promotes inflammatory responses. This study presents the design, synthesis, and evaluation of a series of TLR8 antagonists based on the optimization of previously reported 6-(trifluoromethyl)pyrimidin-2-amines, with targeted modifications to further explore structure-activity relationships (SAR) and increase potency. A two-step synthesis involving nucleophilic aromatic substitution and Suzuki coupling was used to prepare two series of new compounds. The biological evaluation revealed that compounds <b>14</b> and <b>26</b> exhibited promising TLR8 antagonistic activity with <i>IC</i> <sub>50</sub> values of 6.5 and 8.7 μmol L<sup>-1</sup>, respectively. Compound <b>14</b> showed reduced cell viability at higher concentrations, while compound <b>26</b> showed no cytotoxic effects, making it a promising candidate for further investigation.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Optimization of 6-(trifluoromethyl)pyrimidine derivatives as TLR8 antagonists.\",\"authors\":\"Nika Strašek Benedik, Valerij Talagayev, Troy Matziol, Ana Dolšak, Izidor Sosič, Günther Weindl, Gerhard Wolber, Matej Sova\",\"doi\":\"10.2478/acph-2025-0011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Toll-like receptors (TLRs) are essential for the innate immune system as they recognize pathogen-associated molecular patterns and trigger immune responses. Overactivation of TLR8 by endogenous nucleic acids is associated with the development of autoimmune diseases and promotes inflammatory responses. This study presents the design, synthesis, and evaluation of a series of TLR8 antagonists based on the optimization of previously reported 6-(trifluoromethyl)pyrimidin-2-amines, with targeted modifications to further explore structure-activity relationships (SAR) and increase potency. A two-step synthesis involving nucleophilic aromatic substitution and Suzuki coupling was used to prepare two series of new compounds. The biological evaluation revealed that compounds <b>14</b> and <b>26</b> exhibited promising TLR8 antagonistic activity with <i>IC</i> <sub>50</sub> values of 6.5 and 8.7 μmol L<sup>-1</sup>, respectively. Compound <b>14</b> showed reduced cell viability at higher concentrations, while compound <b>26</b> showed no cytotoxic effects, making it a promising candidate for further investigation.</p>\",\"PeriodicalId\":7034,\"journal\":{\"name\":\"Acta Pharmaceutica\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Pharmaceutica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2478/acph-2025-0011\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmaceutica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/acph-2025-0011","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

toll样受体(TLRs)对先天免疫系统至关重要,因为它们识别病原体相关的分子模式并引发免疫反应。内源性核酸对TLR8的过度激活与自身免疫性疾病的发展有关,并促进炎症反应。本研究在对先前报道的6-(三氟甲基)嘧啶-2胺进行优化的基础上,设计、合成和评价了一系列TLR8拮抗剂,并进行了针对性的修饰,以进一步探索结构-活性关系(SAR)并提高效价。采用亲核芳香取代和Suzuki偶联两步法合成了两个系列的新化合物。生物学评价表明,化合物14和26具有较好的TLR8拮抗活性,ic50值分别为6.5和8.7 μmol L-1。化合物14在较高浓度下细胞活力降低,而化合物26无细胞毒作用,是进一步研究的有希望的候选者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Optimization of 6-(trifluoromethyl)pyrimidine derivatives as TLR8 antagonists.

Toll-like receptors (TLRs) are essential for the innate immune system as they recognize pathogen-associated molecular patterns and trigger immune responses. Overactivation of TLR8 by endogenous nucleic acids is associated with the development of autoimmune diseases and promotes inflammatory responses. This study presents the design, synthesis, and evaluation of a series of TLR8 antagonists based on the optimization of previously reported 6-(trifluoromethyl)pyrimidin-2-amines, with targeted modifications to further explore structure-activity relationships (SAR) and increase potency. A two-step synthesis involving nucleophilic aromatic substitution and Suzuki coupling was used to prepare two series of new compounds. The biological evaluation revealed that compounds 14 and 26 exhibited promising TLR8 antagonistic activity with IC 50 values of 6.5 and 8.7 μmol L-1, respectively. Compound 14 showed reduced cell viability at higher concentrations, while compound 26 showed no cytotoxic effects, making it a promising candidate for further investigation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta Pharmaceutica
Acta Pharmaceutica PHARMACOLOGY & PHARMACY-
CiteScore
5.20
自引率
3.60%
发文量
20
审稿时长
>12 weeks
期刊介绍: AP is an international, multidisciplinary journal devoted to pharmaceutical and allied sciences and contains articles predominantly on core biomedical and health subjects. The aim of AP is to increase the impact of pharmaceutical research in academia, industry and laboratories. With strong emphasis on quality and originality, AP publishes reports from the discovery of a drug up to clinical practice. Topics covered are: analytics, biochemistry, biopharmaceutics, biotechnology, cell biology, cell cultures, clinical pharmacy, drug design, drug delivery, drug disposition, drug stability, gene technology, medicine (including diagnostics and therapy), medicinal chemistry, metabolism, molecular modeling, pharmacology (clinical and animal), peptide and protein chemistry, pharmacognosy, pharmacoepidemiology, pharmacoeconomics, pharmacodynamics and pharmacokinetics, protein design, radiopharmaceuticals, and toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信